A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma — Celestimo  

Relapsed or Refractory Follicular Lymphoma Clinical Trial

Official title: Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy

Status Recruiting

Clinical Trial Summary

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Follicular
• Relapsed or Refractory Follicular Lymphoma

• NCT number: NCT04712097
• Study type: Interventional
• Source: Hoffmann-La Roche
• Contact: Reference Study ID: GO42909 https://forpatients.roche.com/
• Phone: 888-662-6728
• Email: global-roche-genentech-trials@gene.com
• Status: Recruiting
• Phase: Phase 3
• Start date: October 27, 2021
• Completion date: May 1, 2029